- Mednow (MNOW) has provided guidance on its upcoming fiscal Q3 2022 quarterly earnings, which will be released in June
- The company is forecast to achieve quarterly revenues of $5 – $5.5M, a QoQ growth of approximately 175 per cent
- Revenue for the calendar year 2023 is forecast to range between C$105M and C$110M
- The gross margin is expected to average at approximately 25%, with 110K – 120K active patients
- Karim Nassar, CEO of Mednow sat down with Shoran Devi to discuss the results
- Mednow is a healthcare technology company
- Mednow Inc. (MNOW) opened trading at $0.74 per share
Mednow (MNOW) has provided guidance on its upcoming fiscal Q3 2022 quarterly earnings, which will be released in June.
In fiscal Q3 2022, Mednow is forecast to achieve quarterly revenues of $5 – $5.5M, representing quarter-over-quarter growth of approximately 175 per cent.
For the calendar year 2023, Mednow is expected to produce an adjusted EBITDA of approximately $5M – $10M. Revenue for 2023 is forecast to range between C$105M and C$110M. The gross margin is expected to average at approximately 25 per cent, with 110K – 120K active patients.
Karim Nassar, CEO and Co-Founder of Mednow Inc. sat down with Shoran Devi to discuss the results.
Mednow is a Canadian-based healthcare technology company. Mednow.ca provides virtual pharmacy and telemedicine services, as well as doctor home visits.
Mednow Inc. (MNOW) opened trading at $0.74 per share.